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by caMP-elevating agents
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We have shown that cholera toxin (CT) and other cyclic AMP (cAMP)-elevating agents 
induce upregulation of the inhibitory molecule CTLA-4 in human resting CD4+ T lym-
phocytes, which following the treatment acquired suppressive functions. In this study, 
we evaluated the effect of cAMP-elevating agents on human CD4+CD25+ T cells, 
which include the T regulatory cells (Tregs) that play a pivotal role in the maintenance 
of immunological tolerance. We found that cAMP-elevating agents induce upregulation 
of CTLA-4 in CD4+CD25− and further enhance its expression in CD4+CD25+ T cells. 
We observed an increase of two isoforms of mRNA coding for the membrane and the 
soluble CTLA-4 molecules, suggesting that the regulation of CTLA-4 expression by 
cAMP is at the transcriptional level. In addition, we found that the increase of cAMP 
in CD4+CD25+ T cells converts the CD4+CD25+Foxp3− T cells in CD4+CD25+Foxp3+ 
T cells, whereas the increase of cAMP in CD4+CD25− T cells did not upregulate Foxp3 in 
the absence of activation stimuli. To investigate the function of these cells, we performed 
an in vitro suppression assay by culturing CD4+CD25+ T cells untreated or pre-treated 
with CT with anti-CD3 mAbs-stimulated autologous peripheral blood mononuclear 
cell. We found that CT enhances the inhibitory function of CD4+CD25+ T cells, CD4+, 
and CD8+ T cell proliferation and IFNγ production are strongly inhibited by CD4+CD25+ 
T cells pre-treated with cAMP-elevating agents. Furthermore, we found that CD4+CD25+ 
T lymphocytes pre-treated with cAMP-elevating agents induce the upregulation of CD80 
and CD86 co-stimulatory molecules on immature dendritic cells (DCs) in the absence of 
antigenic stimulation, however without leading to full DC maturation. These data show 
that the increase of intracellular cAMP modulates the phenotype and function of human 
CD4+CD25+ T cells.
Keywords: cyclic aMP, caMP-elevating agents, cTla-4, costimulation, Treg lymphocytes
Abbreviations: cAMP, cyclic AMP; CT, cholera toxin; FSK, forskolin.
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inTrODUcTiOn
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is expressed on T 
lymphocytes and plays an important role in the down-modulation 
of immune responses (1, 2). There is accumulating evidence that 
CTLA-4 plays a dual role, as a mediator of cell-intrinsic negative 
signals to activated effector T cells and as essential molecule for 
the function of naturally occurring Foxp3+ regulatory T cells 
(Treg) (3, 4). T regulatory cells constitutively express CTLA-4 
(5) and deficiency of the molecule in Foxp3+ Tregs impairs 
their in vivo and in vitro suppressive function (6–9). Recently, 
it became evident that CTLA-4 is a negative regulator also on 
Tregs by limiting their peripheral expansion (10, 11). CTLA-4 
is a structural homolog of CD28 and shares with it the ligands 
CD80 and CD86. However, engagement of CD28 or CTLA-4 
delivers opposing signals to T cells, while CD28 promotes 
IL-2 production and T cell proliferation, CTLA-4 engagement 
results in impaired IL-2 production and T cell unresponsive-
ness (12). Furthermore, while CD28 is constitutively expressed 
on the surface of resting T cells, CTLA-4 is mainly expressed 
in intracellular recycling vesicles and it is transported to the 
cell-surface upon T cell activation (13). We have previously 
shown that cholera toxin (CT) and other cyclic AMP (cAMP) 
elevating agents induce upregulation of the inhibitory molecule 
CTLA-4 in human resting CD4+ T lymphocytes (14) and that 
human CD4+ T lymphocytes pre-treated with CT inhibit the 
proliferation of autologous peripheral blood mononuclear cells 
(PBMC) (15). In this study, we evaluated whether the increase 
of intracellular cAMP in the absence of stimulation modulate 
CTLA-4 expression on human CD4+CD25+ T cells.
Cyclic AMP as a second messenger play a role pivotal in 
cells of the immune system and this has been widely described 
(16). The elevation of intracellular cAMP in T lymphocytes has 
an inhibitory effect on proliferation and on the production of 
IL-2 by inducing cAMP-dependent ICER expression, which is 
associated with decreased IL-2 production (17, 18) and has been 
shown to affect T cell activation events at early stages (19). It has 
been described that Treg harbor elevated levels of intracellular 
cAMP that play a role in Treg-mediated suppression by trans-
ferring of cAMP to target cells via cell contact-dependent gap 
junctions (20). Here, we evaluated the phenotype and function of 
CD4+CD25+ T cells after treatment with cAMP-elevating agents. 
We found that increase of intracellular cAMP in CD4+CD25+ T 
cells upregulates the inhibitory molecule CTLA-4 and converts 
CD25+ T cells into Foxp3+ cells enhancing their suppressive 
capacity. Furthermore, we observed that in the absence of 
antigenic stimulation CD4+CD25+ T cells with increased cAMP 
levels induce the upregulation of CTLA-4 ligands CD80 and 
CD86 co-stimulatory molecules on target APC.
MaTerials anD MeThODs
Media and reagents
RPMI 1640 supplemented with 2  mM l-glutamine, 1% non-
essential amino acids, 1% pyruvate, 100  U/ml penicillin, 
100  μg/ml streptomycin (Gibco, NY, USA), and 10% FCS 
(Euroclone, Pero, MI, USA) was used as complete medium in all 
cultures. Anti-CD3 (clone UCHT1) mAbs were purchased from 
Immunotech (Westbrook, ME, USA). CT was purchased from 
List Biological Laboratories (Campbell, CA, USA); forskolin 
(FSK) was purchased from Sigma Chemicals (Co., St Louis, 
MO, USA).
lymphocytes Purification and 
cell cultures
Human studies were performed in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki. PBMC were 
isolated from freshly collected buffy coats obtained from healthy 
voluntary blood donors (Bloodbank of University “la Sapienza”, 
Rome, Italy). The study was approved by the ethical board of 
our Institute. Cells were isolated by Ficoll-Hypaque (Pharmacia, 
Sweden) density centrifugation. CD4+ T lymphocytes were 
purified by negative selection using an immunomagnetic cell 
sorting (Miltenyi Biotec, Bergish Gladback, Germany). CD4+ 
T cells were further purified into CD4+CD25− and CD4+CD25+ 
T cells by positive selection using phycoerythrin (PE)-anti-CD25 
and anti-PE microbeads. Briefly, PBMC were labeled using a 
cocktail of hapten-conjugated mAbs anti-CD8, CD11b, CD16, 
CD19, CD36, and CD56 molecules and MACS MicroBeads 
coupled to an anti-hapten monoclonal antibody. The magneti-
cally labeled cells were depleted by retaining them on a column 
using MidiMACS cell separator, purity of both CD4+CD25− and 
CD4+CD25+ T cells was >98%. Alternatively, for mRNA stud-
ies CD4+CD25− and CD4+CD25+ T cells were stained with 
anti-CD4 and anti-CD25 mAbs and isolated by flow cytometry 
using a BD FACSVantage cell sorter. Purified CD4+CD25+ T cells 
(5 × 106/ml) were incubated in the absence or in the presence of 
CT (1 μg/ml) or FSK (10 μM). After 24 h, cells were harvested, 
washed extensively (three times), and stained for flow cytometry 
analysis.
Flow cytometry analysis
Fluorescein (FITC)-, or PE-conjugated anti-CD4, CD8, CTLA-4, 
CD25, CD127 mAbs and their isotype-matched controls pur-
chased from BD Biosciences, San Diego, CA, USA, and Foxp3 
from eBioscience, San Diego, CA, USA, were used for direct 
immunofluorescence staining. Detection of CTLA-4 and Foxp3 
was performed by intracellular staining. Briefly, cells were washed 
twice in PBS, 1% BSA and 0.1% sodium azide and stained with 
anti-CD4 or CD25 mAbs on the membrane for 15 min at 4°C. 
Samples were then fixed in 4% paraformaldehyde for 5 min at 
4°C, incubated with anti-CTLA-4 or anti-Foxp3 mAbs, diluted in 
PBS, 1% BSA and 0.5% saponin. Cells were finally washed twice 
in PBS, 1% BSA, 0.1% saponin, and acquired on a FACSCalibur™ 
instrument running CellQuest software.
cTla-4 mrna analysis by rT-Pcr
Total RNA was extracted using RNAFast reagent (Life 
Technology, Carlsbad, CA, USA) according to the manufac-
turer’s recommendations. The single-stranded cDNA was 
synthesized using 1 μg of RNA by reverse transcription using 
random examers (Invitrogen, Carlsbad, CA, USA). PCRs 
were performed with cDNA corresponding to 10  ng of RNA, 
3Riccomi et al. Enhanced Treg Suppression by cAMP
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 358
Taq polymerase (Invitrogen, Carlsbad, CA, USA) and prim-
ers designed to amplify the entire coding sequence of CD152: 
5′-ATGGCTTGCCTTGGATTTCAGCGGCACAAGG-3′ and 
5′-TCAATTGATGGGAATAAAATAAGGCTGAAATTGC-3′. 
PCR was as follows: 94°C for 5 min, 30 cycles 94°C for 30 s, 58°C 
for 30 s, and 72°C for 30 s followed by a final extension at 72°C for 
7 min. The amplified fragments were separated on 1% agarose gel 
and visualized by ethidium bromide. RNA integrity and cDNA 
synthesis were verified by amplifying β2-microglobulin cDNA. 
The intensity of the bands was directly quantified by Image QuaNT 
software (Amersham Pharmacia Biotech, Piscataway, NJ, USA), 
which measures a volume report (expressed as arbitrary units, 
a.u.) by integrating the area of the bands and their OD. CTLA-4 
mRNA values were normalized to those of β2-microglobulin and 
expressed as a.u.
Proliferation assay and cytokines 
evaluation
Purified CD4+CD25+ T cells (5 ×  106/ml) were incubated in 
presence or absence of CT (1 μg/ml). After 24 h, cells were har-
vested, irradiated (3000 rad), extensively washed, and incubated 
for 1 h in round-bottom, 96-well plates with autologous PBMC 
(6 × 104) at different ratios (1:1, 0.5:1, 0.25:1) in triplicates. Then, 
anti-CD3 mAb (0.5 μg/ml) was added to the cultures, and the 
proliferation was evaluated by 3H-thymidine incorporation. 
Plates were incubated for 48  h at 37°C with 5% CO2, culture 
supernatants were collected and frozen at −80°C for cytokine 
determination by Elisa assay (Pierce Endogen Rockford, IL, 
USA) and 3H-thymidine (Amersham, Aylesbury, UK) was added 
(1 μCi/well). After 18 h, cells were harvested, and incorporated 
radioactivity was measured by microβ-counting. Alternatively, 
PBMC (107/ml) were washed in PBS 1% FCS and incubated 
with 2.5  μM of carboxyfluorescein succinimidyl ester (CFSE) 
(Molecular probes, Eugene, OR, USA) for 10 min at 37°C. The 
reaction was quenched by the addition of 10 times volume of 
cold RPMI 10% FCS incubated for 5 min at 4°C, then washed 
three times with RPMI 10% FCS. Cells (8  ×  104/well) and 
co-cultured with CT pre-treated and untreated CD4+CD25+ T 
cells (8 × 104/well) and stimulated with anti-CD3 mAbs (0.5 μg/
ml). After 4 days, cells were double stained with anti-CD4-PE 
and anti-CD8-Cy5 mAbs or with anti-CD25-Cy5 and anti-
Foxp3-PE and acquired on a FACSCaliburTM instrument run-
ning CellQuest software.
Transwell experiments
In transwell assays, cells were separated by a membrane (6.5 mm 
diameter, 0.4 mm pore size) in 24-well plates (Costar, Corning, 
NY, USA). The lower compartments of the wells contained 
PBMC (1 ×  106). The upper compartments contained medium 
alone, untreated or CT-pre-treated CD4+CD25+ T cells (1 × 106). 
In parallel, untreated or CT-pre-treated CD4+CD25+ T lympho-
cytes were placed in the lower chambers in contact with PBMC. 
Cultures were stimulated with anti-CD3 mAb (0.5  μg/ml) for 
48 h, and proliferation was evaluated by harvesting the cells from 
the lower compartments and by incubating them in the presence 
of 3H-thymidine for further 18 h.
Monocytes Purification and cell cultures
Human monocytes were purified from PBMC of healthy donors 
by positive selection using anti-CD14-conjugated magnetic 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Cells recovered were 95–99% CD14+, as determined by flow 
cytometry using the FITC conjugate anti-human CD14 mAb (BD 
Biosciences, San Diego, CA, USA). Monocyte-derived DCs were 
generated by culturing isolated monocytes for 5 days in complete 
RPMI medium with 35 ng/ml rhIL-4 and 50 ng/ml rhGM-CSF 
(Immunological Sciences, Rome, Italy). Immature DCs were 
co-cultured for 48  h with CD4+CD25+ T cells pre-treated or 
untreated with CT or in presence of lipopolysaccharide (LPS) 
(200 ng/ml) from Sigma Chemical Co, CT, USA (1 μg/ml) or FSK 
10 μM). Cells were stained with FITC-, PE-, or PECy7-conjugated 
anti-HLA-DR, anti-HLA-A,B,C, anti-CD80, anti-CD83 and anti-
CD86 mAbs. All samples were acquired on a FACSCaliburTM 
instrument running CellQuest software.
statistical analysis
Microsoft Excel (Microsoft Corp., Redmond, WA, USA) was 
used for statistical analysis. Data were expressed as mean ± SEM, 
and statistical significance was determined by Student’s t-test, 
p ≤ 0.05 was considered statistically significant.
resUlTs
cyclic aMP Upregulates cTla-4 
Molecules in cD4+cD25− and in 
cD4+cD25+ T lymphocytes
We have shown that CT and other cAMP elevating agents induce 
upregulation of the inhibitory molecule CTLA-4 in human 
resting CD4+ T lymphocytes (14). In this study, to investigate 
whether intracellular increase of cAMP affects on the expression 
of CTLA-4 on CD4+CD25+ T cells, we evaluated the effects of 
cAMP-elevating agents on CD4+CD25− and CD4+CD25+ T lym-
phocytes. Cells were purified by immunomagnetic cell sorter, the 
purity of the CD4+CD25− and CD4+CD25+ T cells and the gate 
strategy is shown in Figure 1A and cultured in the presence and in 
the absence of CT (1 μg/ml) or FSK (10 μM), a drug that directly 
activates adenylyl cyclases, for 24 h and analyzed for the CTLA-4 
expression by intracellular staining. We found that the increase of 
intracellular cAMP enhances the expression of CTLA-4 on both 
CD4+CD25− and CD4+CD25+ T cells (Figure 1B). Although it 
is known that CD4+CD25+ Tregs constitutively express CTLA-4 
and that its expression is upregulated following activation (5, 10, 
21), the treatment with cAMP-elevating agents further enhances 
its expression in CD4+CD25+ T cells in the absence of activation 
stimuli (Figure 1B).
Next, we evaluated whether cAMP-dependent upregulation of 
CTLA-4 correlated with an increase of mRNA, we analyzed the 
CTLA-4 mRNA in CD4+CD25− and CD4+CD25+ T cells puri-
fied by FACSvantage cell sorting after staining with anti-CD25 
mAb. Cells were cultured in the presence of CT and the mRNA 
was analyzed after 4 h. We observed an increase of two mRNA 
transcripts corresponding to the membrane (672  bp) and the 
soluble (550 bp) molecule of CTLA-4 (22) (Figures 1C,D). These 
FigUre 1 | Upregulation of cTla-4 induced by caMP in the absence of T cell activation. CD4+CD25− and CD4+CD25+ T cells were purified by 
immunomagnetic cell sorting, (a) shows the gate strategy and purity of cells after magnetic separation. Purified cells were cultured in the presence of medium alone 
(medium), CT (1 μg/ml) or FSK (10 μM) for 24 h and then stained with anti-CD4 mAb on the membrane, fixed, permeabilized and stained with anti-CTLA-4. 
Cytofluorimetric analysis was performed on CD4+-gated population. Graphs show the mean of the upregulation of CTLA-4 of five independent donors and the 
*indicates that the differences between CT or FSK treated as compared with untreated cells are significant (p < 0.05), the variations bars correspond to the SEM (B). 
CTLA-4 mRNA was evaluated in CD4+CD25− and CD4+CD25+ T lymphocytes purified by FACSvantage cell sorting after staining with anti-CD25 mAb. Cells were 
cultured in the presence or absence of CT and the mRNA was analyzed after 4 h. RNA integrity and cDNA synthesis were verified by amplifying β2-microglobulin 
cDNA. An irrelevant cDNA from human tumor cell line (THP-1) has been included in the amplification (lane 6) of (c). The graph (D) represents CTLA-4 mRNA 
quantification of the two mRNA transcripts (672 and 550 bp fragments), both normalized to those of β2-microglobulin. One of two experiments performed is shown.
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FigUre 2 | Upregulation of Foxp3 induced by caMP in the absence of T cell activation. CD4+CD25− and CD4+CD25+ T cells were purified by 
immunomagnetic cell sorter, cultured in the presence of medium alone (medium), CT (1 μg/ml) or FSK (10 μM) for 24 h and stained with anti-CD4 and anti-CD127 
mAb (B) or with anti-CD4 and on membrane and the fixed, permeabilized and stained with anti-Foxp3. Cytofluorimetric analysis was performed on CD4+-gated 
population. Graphs show the mean of the upregulation of Foxp3 (a) and down-modulation of CD127 (B) of five independent donors and the * indicates that the 
differences between CT or FSK treated as compared with untreated cells are significant (p < 0.05).
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results show that the increase of intracellular cAMP results in 
the upregulation of soluble and membrane CTLA-4 at mRNA 
and protein levels in T lymphocytes and that this occurs in the 
absence of full T cell activation.
cyclic aMP elevating agents induce the 
expression of Foxp3 in cD4+cD25+ 
T lymphocytes
Next, we asked whether the increase of intracellular cAMP could 
affect the expression of Foxp3 in CD4+CD25− and in CD4+CD25+ 
T lymphocytes. Cells were purified by immunomagnetic cell 
sorter, cultured in the presence and in the absence of CT (1 μg/
ml) or FSK (10 μM) for 24 h and analyzed for Foxp3 expression 
by intracellular staining. The percentage of Foxp3+ cells among 
CD4+CD25+ T lymphocytes was evaluated and was 61 ± 7%. We 
found that the increase of intracellular cAMP by either CT or 
FSK enhances the expression of Foxp3 on CD4+CD25+ T cells, 
whereas it did not change Foxp3 expression on CD4+CD25− 
T  cells (Figure  2A). Furthermore, we observed a significant 
down-modulation of CD127 following CT or FSK treatment on 
both CD4+CD25− and on CD4+CD25+ T cells (Figure 2B). These 
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data indicate that the increase of cAMP in CD4+CD25+ T cells 
converts the CD4+CD25+Foxp3− T cells in CD4+CD25+Foxp3+ 
Tregs, whereas the increase of cAMP in CD4+CD25− T cells did 
not upregulate Foxp3 in the absence of activation stimuli.
enhanced suppression of T cell 
Proliferation by cD4+cD25+ 
T lymphocytes Pre-Treated with cT
In order to analyze the function of CD4+CD25+ T lymphocytes 
pre-treated with cAMP-elevating agents, we compared the sup-
pressive capacity of untreated and CT pre-treated CD4+CD25+ 
T cells. PBMC isolated from healthy donors were cultured with 
autologous untreated or CT-pre-treated CD4+CD25+ T  cells at 
different ratios (1/1, 1/0.5, 1/0.25) and stimulated with anti-
CD3 mAbs (0.5  μg/ml). The proliferation was evaluated by 
3H-thymidine incorporation after 66 h of culture. According to 
the higher proportion of Foxp3+ T cells in the CT-pre-treated 
CD4+CD25+ T lymphocytes, we found that CD4+CD25+ 
T lymphocytes pre-treated with CT showed a higher capacity of 
inhibiting the proliferation of autologous PBMC as compared to 
untreated CD4+CD25+ T cells. The inhibition was dose depend-
ent (Figure 3A). To investigate whether the suppression mediated 
by CT-pre-treated CD4+CD25+ T lymphocytes was cell-to-cell 
contact dependent, we performed experiments using transwell. 
PBMC were placed in the lower chambers of the transwell and 
untreated or CT-pre-treated CD4+CD25+ T lymphocytes in 
the upper chambers. In parallel, untreated or CT-pre-treated 
CD4+CD25+ T lymphocytes were placed in the lower chambers 
in contact with PBMC. Cultures were stimulated with anti-CD3 
mAb. We found that CT-pre-treated CD4+CD25+ T cells inhib-
ited the proliferation of autologous, anti-CD3-stimulated PBMC 
in cell-to-cell contact (n = 3, p < 0.05), although the inhibition 
was slightly higher when PBMC and CT-pre-treated CD4+CD25+ 
T  lymphocytes were placed in the upper chambers, the differ-
ences were not significant (Figure 3B). These results suggest that 
the suppression induced by CT-pre-treated CD4+CD25+ T cells 
is mediated by cell-to-cell contact mechanism.
The production of IFNγ was evaluated in the supernatants 
after 48 h of culture and we found that CD4+CD25+ T lympho-
cytes pre-treated with CT and stimulated with anti-CD3 inhibited 
the production of IFNγ in the co-cultures with autologous PBMC 
in a dose-dependent manner, and at larger extent as compared to 
untreated CD4+CD25+ T cells (Figure 3C). To further evaluate 
the inhibitory effects of CD4+CD25+ T lymphocytes treated and 
untreated with CT on either CD4 or CD8 T cell proliferation, 
PBMC were labeled with CFSE and cultured with autologous 
untreated or CT-pre-treated CD4+CD25+ T cells at 1/1 ratio and 
stimulated with anti-CD3 mAbs (0.5 μg/ml). The percentage of 
proliferating CD4+ T cells was evaluated by FACS analysis after 
5  days of culture. Figure  4 shows that both CD4 and CD8 T 
lymphocytes go through a less number of divisions when they 
are co-cultured with CT-pre-treated CD4+CD25+ T lymphocytes 
than with untreated cells as shown by the progressive halving of 
CFSE in dividing cells. These data indicate that CD4+CD25+ T 
lymphocytes with increased cAMP levels have an increased sup-
pression capacity as compared to untreated cells.
enhanced suppression of cD4+cD25+ 
T lymphocytes Pre-Treated with cT 
correlates with higher Foxp3 expression 
in the co-cultures
Next, we evaluated the expression of CD25 and Foxp3 after 5 days 
of co-cultures between CD4+CD25+ T lymphocytes treated or 
untreated with CT (called Effector cells) and CFSE-labeled PBMC 
(called Target cells). Target cells were labeled with CFSE and cul-
tured with autologous untreated or CT-pre-treated CD4+CD25+ 
T cells at 1/1 ratio and stimulated with anti-CD3 mAbs (0.5 μg/
ml). The proliferation was measured as CFSE dilution and the 
expression of CD25 and Foxp3 was evaluated by FACS analysis 
after 5 days of culture. We found that CD25 was upregulated on 
both Effector (178 ± 39 vs. 101 ± 12.5 mfi, p = 0.04) and Target 
cells (43.2 ± 4.1 vs. 23.3 ± 6.1 mfi, p = 0.009) when the Effector 
cells were CT-pre-treated CD4+CD25+ T lymphocytes as com-
pared to when untreated CD4+CD25+ T cells were present in the 
cultures (Figure 5). On the other hand, Foxp3 was upregulated 
on CT-pre-treated CD4+CD25+ T lymphocytes as compared to 
untreated CD4+CD25+ T lymphocytes (98.5 ± 1% vs. 51.7 ± 7.7%, 
p = 0.017) and in a small percentage of the target cells co-cultured 
with CT-pre-treated T lymphocytes as compared to target cells 
co-cultured with untreated cells (6.4  ±  3.1% vs. 1.6  ±  0.9%, 
p = 0.09). These data once again show that the higher suppression 
exerted by CT-pre-treated CD4+CD25+ T lymphocytes correlates 
with the higher expression of Foxp3.
cD4+cD25+ T lymphocytes Pre-Treated 
with caMP-elevating agents induce the 
Upregulation of cD80 and cD86 on 
immature Dcs in the absence of 
antigenic stimulation
It has been reported that CD4+CD25+ T cells affect DCs func-
tions and maturation (23) and that this is due together with 
other molecular mechanisms also to the constitutive expression 
of CTLA-4 on their membrane, which by interacting with its 
ligands leads to DCs suppression (6, 24). Therefore, we asked 
whether CD4+CD25+ T cells pre-treated or untreated with a 
cAMP-elevating agents were able to modulate the expression of 
co-stimulatory molecules on immature DCs in the absence of 
antigenic stimulation. Immature DCs were generated by culturing 
peripheral human monocytes isolated from healthy donors with 
GM-CSF and IL-4 for 5 days. In parallel, autologous CD4+CD25+ 
T lymphocytes were purified and cultured in presence and absence 
of CT for 24 h. After have been extensively washed, CD4+CD25+ 
T lymphocytes were co-cultured with immature DCs for further 
48 h. Dendritic cells (DCs) cultured with LPS were included as 
control to evaluate DC maturation. The expression of CD80 and 
CD86 co-stimulatory molecules on DCs was evaluated by FACS 
analysis. We found that CD4+CD25+ T lymphocytes pre-treated 
with CT induced the upregulation of both CD80 and CD86 
co-stimulatory molecules on DCs as compared to untreated 
CD4+CD25+ T cells, which did not alter the expression of the 
co-stimulatory molecules in the absence of maturation stimuli 
(Figures  6A,C). However, when we analyzed the expression 
FigUre 3 | enhanced suppression of T cell proliferation and iFnγ inhibition by cD4+cD25+ T lymphocytes pre-treated with cT. (a) Immunomagnetically 
purified CD4+CD25+ T lymphocytes isolated from healthy donors were cultured in the presence or absence of CT (1 μg/ml). After overnight incubation, cells were 
washed three times and cultured with autologous PBMC at different ratios (1/1, 1/0.5, 1/0.25) in triplicate in 96-well plates and stimulated with anti-CD3 mAbs. 
(B) Alternatively, PBMC (1 × 106) were placed in the lower wells of transwell and untreated or CT-pre-treated CD4+CD25+ T lymphocytes (1 × 106) were cultured 
either in the upper wells or in the lower chambers in contact with PBMC. Cells were stimulated with anti-CD3 mAb (0.5 μg/ml), and the PBMC proliferation was 
evaluated after 66 h by 3H-thymidine incorporation. The bars indicate the mean of triplicate wells. (c) After 48 h, the amount of IFNγ was valuated in the 
supernatants from the different cultures by ELISA assay in duplicate. The * indicate that the differences between CT-treated as compared with untreated cells are 
significant (p < 0.05). One representative for each of three experiments performed is shown.
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FigUre 4 | inhibitory effects of cD4+cD25+ T lymphocytes pre-treated and untreated with cT on cD4 or cD8 T cell proliferation. Immunomagnetically 
purified CD4+CD25+ T lymphocytes isolated from healthy donors were cultured in the presence or absence of CT (1 μg/ml). After overnight incubation, cells were 
washed three times and cultured with autologous CFSE-labeled PBMC at 1/1 ratio and stimulated with anti-CD3 mAbs. The percentage of proliferating CD4+ 
(a,B) and CD8+ (c,D) T cells was evaluated by FACS analysis after 5 days of culture by CFSE dilution on CD4 and on CD8-gated populations. The numbers within 
the plots and the graphs indicate the percentage of cells that went through 0, 2, 4, and 8 cell divisions. One representative of three performed experiments is shown.
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FigUre 5 | enhanced suppression of cD4+cD25+ T lymphocytes pre-treated with cT correlates with higher Foxp3 expression. Immunomagnetically 
purified CD4+CD25+ T lymphocytes isolated from healthy donors were cultured in the presence or absence of CT (1 μg/ml). After overnight incubation, CD4+CD25+ 
T lymphocytes treated (B) or untreated with CT (a) (called Effector cells) and CFSE-labeled PBMC (called Target cells) cells were cultured at 1/1 ratio and stimulated 
with anti-CD3 mAbs. The proliferation was measured as CFSE dilution in Target cells and the expression of CD25 and Foxp3 was evaluated by FACS analysis after 
5 days of culture on both effector and target cells. Graphs (c) show the mean fluorescence intensity (MFI) values of CD25 and the percentage of Foxp3+ cells in 
Effector and Target cells of three independent experiments and the * indicate that the differences between untreated and CT-pre-treated CD4+CD25+ T cells are 
significant (p < 0.05).
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TaBle 1 | expression of different maturation markers on Dcs co-cultured with untreated or cT-pre-treated cD4+cD25+ T cells.
Medium cD4+cD25+ cT-pre-treated cD4+cD25+ cT FsK lPs
HLA-I 16 ± 7 18.5 ± 4.9 18.5 ± 3.5 21.5 ± 0.7 19.1 ± 0.2 32 ± 7.5*
HLA-DR 68 ± 7 68 ± 1 69.5 ± 7.7 131 ± 4.2* 81 ± 4.9* 135.2 ± 14.3*
CD80 11.7 ± 1.2 12.5 ± 2.6 18.7 ± 2.9* 31 ± 8.4* 28.8 ± 10.6* 37.3 ± 6.86*
CD86 10.6 ± 1.8 16.3 ± 3.9 28.2 ± 3.8* 29.2 ± 2.5* 33 ± 1.4* 55.8 ± 10.7*
CD83 4.5 ± 1.3 5.5 ± 0.7 6.5 ± 0.7 7.1 ± 0.8* 5.73 ± 1.06 17 ± 4.4*
Human CD14 monocytes, isolated from healthy donors’ PBMC, cultured for 5 days with GM-CSF (50 ng/ml) and IL-4 (35 ng/ml) were cultured with medium alone, untreated or CT-
pre-treated CD4+CD25+ T cells or with LPS (200 ng/ml), CT (1 μg/ml) or FSK (10 μM) for 48 h. Cells were stained using directly conjugated mAbs and analyzed by flow cytometry. 
The data are the mean of the expression of these indicated markers of four independent donors and bars are SEM, * indicates that the differences between the indicated treatment 
and the ones cultured in medium alone are significant (p < 0.05).
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of MHC class I and II and that of CD83, a specific maturation 
marker of DCs, we found that CT-pre-treated CD4+CD25+ T cells 
did not change their expression (Table  1). On the other hand, 
LPS induced the upregulation of these markers as expected. These 
results show that CD4+CD25+ T lymphocytes with increased 
cAMP levels induce the upregulation of co-stimulatory molecules 
on DCs without leading to full maturation of DCs. In parallel, 
the effects of cAMP-elevating agents, such as CT and FSK, on 
DC maturation were evaluated as control. We found that both 
CT and FSK led to a significant upregulation of CD80 and CD86 
molecules (Figures 6B,C). In the same experiments, although we 
observed a significant upregulation of MHC class I and II and 
that of CD83 by CT, with FSK we observed a significant upregula-
tion only of MHC class II and not of MHC class I and CD83 
(Table 1). These data suggest that the increase of cAMP, unless 
is not sustained like when is induced by CT, lead to partial DC 
maturation. Altogether, these findings indicate that the molecular 
effects of the cAMP on the immune responses are the result from 
the integration of inhibitory as well as co-stimulatory stimuli on 
different cell types.
DiscUssiOn
The integration of co-stimulatory and inhibitory signals is a 
critical aspect of the immune responses. CTLA-4 is an inhibitory 
receptor expressed on T lymphocytes, which is normally upregu-
lated upon T cell activation and is involved in the termination 
of immune responses. On the other hand, the natural ligands 
of CTLA-4, CD80, and CD86 co-stimulatory molecules are 
upregulated following APC activation and maturation (25). We 
have shown that CT and other cAMP-elevating agents induce 
upregulation of the inhibitory molecule CTLA-4 in human 
resting CD4+ T lymphocytes (14) and that these cells with 
increased intracellular cAMP levels exert inhibitory function by 
releasing cAMP (15). Since CTLA-4 plays a critical role in cell 
contact-dependent Treg-mediated in vitro and in vivo suppres-
sion (6, 21), we asked whether signals that lead to an increase 
of intracellular cAMP would modulate CTLA-4 expression 
in CD4+CD25+ T cells. It is known that Tregs constitutively 
express CTLA-4 and that its expression is upregulated in the 
presence of activation stimuli (5, 10, 21). Here, we show that 
cAMP-elevating agents enhance the expression of this inhibitory 
molecule in CD4+CD25− and further upregulate its expression 
in CD4+CD25+ T cells. These data are in accordance with others 
showing that different cAMP-elevating agents, such as adenosine 
or β-adrenergic agonists, induce CTLA-4 upregulation in Treg 
(26–28). We observed increased CTLA-4 mRNA in cells treated 
with CT. It is known that two mRNA isoforms coding for soluble 
and membrane CTLA-4 are expressed in resting T lymphocytes 
(22). Interestingly, the upregulation of human CTLA-4 by cAMP-
elevating agents in CD4+CD25+ T lymphocytes involves both 
variants of mRNA transcripts. The upregulation of CTLA-4 by 
cAMP could be regulated at the transcriptional level or due to 
changes in the stability of CTLA-4 mRNA. Although the contri-
bution of sCTLA-4 to immune regulation has been less studied, 
it has been reported to play a role as regulator of T cell responses 
and to potentiate Treg suppression functions (29–31). These 
findings are consistent with the enhanced suppression of cytokine 
production and T cell proliferation on both CD4+ and CD8+ T cell 
populations exerted by CD4+CD25+ T lymphocytes pre-treated 
with CT. Furthermore, consistent with the higher suppression 
capacity mediated by CD4+CD25+ T cells pre-treated with CT 
as compared with untreated cells is the increased percentage of 
CD4+CD25+Foxp3+ found after treatment with CT or FSK. This is 
in agreement with other findings showing that signaling through 
A2A adenosine or through β-adrenergic receptors, which leads 
to an increase of intracellular cAMP, induces the expression of 
Foxp3 on CD4+Foxp3− cells (26–28). Indeed, the Foxp3 gene was 
described to bear an enhancer in its first intron that is depend-
ent on a cAMP response element binding protein (CREB) site 
(32). In addition, our results indicate that the increase of cAMP 
in CD4+CD25+ T cells converts the CD4+CD25+Foxp3− T cells 
into CD4+CD25+Foxp3+ Tregs, whereas the increase of cAMP in 
CD4+CD25− T cells did not upregulate Foxp3 in the absence of 
activation stimuli following 24-h treatment. These data suggest 
that the presence of CD4+CD25+Foxp3+ cells in the cultures is 
needed for the upregulation of Foxp3 mediated by cAMP-ele-
vating agents. Although the molecular mechanisms underlying 
the upregulation of CTLA-4 and Foxp3 in CD4+CD25+ T cells 
it is not completely understood, at this stage, we can assess by 
using the CT, which constitutively increases the intracellular 
cAMP and FSK, which only transiently increases cAMP, that 
these effects are mediated by cAMP and that a single shot of 
cAMP, which in vivo could be caused by different factors, such as 
neurotransmitters or catecholamine, can change the phenotype 
and functions of CD4+CD25+ T cells. Increase of cAMP activates 
downstream pathways that are mainly the canonical PKA and the 
non-canonical EPAC pathways. The cAMP/PKA signaling leads 
FigUre 6 | Upregulation of cD80 and cD86 on immature Dcs by cD4+cD25+ T lymphocytes pre-treated with caMP-elevating agents. Immature DCs 
were generated by culturing peripheral human monocytes isolated from healthy donors with GM-CSF and IL-4 for 5 days. In parallel, autologous CD4+CD25+ T 
lymphocytes were purified and cultured in presence and absence of CT for 24 h. After have been extensively washed CD4+CD25+ T lymphocytes were co-cultured 
with immature DCs for further 48 h. Dendritic cells cultured with LPS (200 ng/ml) (a,c), CT or FSK (B) were included as control. The expression of CD80 and CD86 
co-stimulatory molecules on DCs was evaluated by FACS analysis. Graphs in panel (c) show the mean of the CD80 and CD86 expression of five independent 
donors and the * indicates that the differences as compared to untreated cells are significant (p < 0.05).
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to the phosphorylation of the CREB, which has been described 
to promote the TGFβ-mediated generation of Tregs from naive 
T cells and contribute to the expression of Foxp3 in these induced 
Tregs. In light of this, we can hypothesize that the upregulation 
of CTLA-4 and Foxp3 on CD4+CD25+ T cells are mediated by 
PKA/CREB pathway, however, further studies are needed to fully 
clarify the molecular mechanism.
Cyclic AMP has been regarded to mediate Treg suppres-
sion (20). It was demonstrated that cAMP is transferred from 
Tregs into activated target responder T cells via gap junctions 
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(20). It was also shown that direct contact between Tregs and 
conventional T cells can induce ICER expression in responder T 
cells by cAMP-dependent mechanism, which is associated with 
down-modulation of IL-2 production (20, 33–36). Furthermore, 
targeting ICER with RNAi in responder CD4+ T cells led to the 
inhibition of Treg-mediated suppression (34–36). In addition, 
we have previously shown that CD4+ T lymphocytes treated with 
cAMP-elevating agents release cAMP in the extracellular com-
partment in the absence of cell death (15) and that extracellular 
cAMP could be sensed by cells of the immune system through 
CD73 ecto-5′-nucleotidase and A2A and A2B adenosine recep-
tors (37). Furthermore, it is known that Tregs express high levels 
of ecto-enzymes CD73 and CD39, which generate extracellular 
adenosine (38–40) and adenosine through the A2A adenosine 
receptor pathway, not only potentiate the suppression function of 
Treg but also promote their expansion (26, 27, 40–42). Therefore, 
we can hypothesize that extracellular cAMP could be converted 
into adenosine through the extracellular cAMP-adenosine path-
way, which has been described in different cell types included 
cells of the immune system (37) and acts on the effector cells 
through the adenosine receptors. This could in part explain the 
need of CD4+CD25+Foxp3+ Tregs, which express high levels of 
CD73 to speed up the conversion of CD4+CD25+Foxp3− T cells 
into CD4+CD25+Foxp3+ Tregs in the presence of cAMP-elevating 
agents. On the other hand, intracellular cAMP could be transferred 
to the target cells through the gap junctions and inhibit T cell 
proliferation or modulate APC function. These two mechanisms 
are not necessary mutually exclusive and both lead to an increase 
of intracellular cAMP in target cells. Consistent with this are the 
effects mediated by CD4+CD25+ T lymphocytes pre-treated with 
CT on DCs. In line with our previous observations (43, 44), the 
increase of cAMP in immature DC in the absence of maturation 
stimuli, unless is constitutive such as that induced directly by 
CT, leads to moderate upregulation of CD80 and CD86 co-
stimulatory molecules on DCs and did not change the expression 
of MHC class I and II and that of CD83, a specific DC maturation 
marker as compared to treatment with LPS, which induced full 
maturation of DCs. On the other hand, it has been reported that 
CD4+CD25+ T cells affect DCs functions and maturation (23, 
24) by down-modulating CD80 and CD86 through CTLA-4, 
which by interacting with its ligands leads to DCs alteration and 
sequestration (6, 23, 24). Our data, which could apparently be in 
contrast with these findings could be explained by taking into 
account that the effect of CT pre-treated CD4+CD25+ T cells on 
DCs was observed in the absence of maturation stimuli and anti-
genic stimulation, reminding the effects of cAMP on immature 
DCs (43, 44). The upregulation of co-stimulatory molecules on 
APC could concur to a stronger interaction between Treg and 
APC and further prevent them to interact with and stimulate 
responder T cells. On the contrary, it is known that the capacity to 
increase cAMP is an important feature of several adjuvants, which 
strongly stimulate the immune responses (45). We have reported 
that even if cAMP impairs the differentiation of monocytes into 
DCs, it induces professional myeloid APC (46). Therefore, the 
overall role of cAMP on the immune responses according with 
its inhibitory and co-stimulatory stimuli on different cell types 
remains to be further investigated. This concept was recently 
reviewed by Raker et al. (47).
In conclusion, we show that cAMP plays different roles 
according to cell types upregulates CTLA-4 and Foxp3 on 
CD4+CD25+ T cells in the absence of activation stimuli and Tregs 
pre-treated with cAMP-elevating agents induce the upregulation 
of CD80 and CD86 on APC. The manipulation of intracellular 
and extracellular cAMP could be a tool for therapeutic purposes 
in autoimmune and inflammatory diseases.
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